Norway · Delayed Price · Currency is NOK General Oceans ASA Statistics
Total Valuation
OSL:GENO has a market cap or net worth of NOK 3.01 billion. The enterprise value is 2.62 billion.
| Market Cap | 3.01B |
| Enterprise Value | 2.62B |
Important Dates
The last earnings date was Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OSL:GENO has 190.11 million shares outstanding. The number of shares has increased by 6.78% in one year.
| Current Share Class | 190.11M |
| Shares Outstanding | 190.11M |
| Shares Change (YoY) | +6.78% |
| Shares Change (QoQ) | +2.07% |
| Owned by Insiders (%) | 43.88% |
| Owned by Institutions (%) | 17.09% |
| Float | 42.94M |
Valuation Ratios
The trailing PE ratio is 24.35 and the forward PE ratio is 13.37.
| PE Ratio | 24.35 |
| Forward PE | 13.37 |
| PS Ratio | 2.20 |
| PB Ratio | 2.37 |
| P/TBV Ratio | 3.51 |
| P/FCF Ratio | 37.82 |
| P/OCF Ratio | 26.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.88, with an EV/FCF ratio of 32.89.
| EV / Earnings | 22.30 |
| EV / Sales | 1.91 |
| EV / EBITDA | 11.88 |
| EV / EBIT | 18.90 |
| EV / FCF | 32.89 |
Financial Position
The company has a current ratio of 3.27, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.27 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 1.41 |
| Interest Coverage | 7.57 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.05% |
| Return on Capital Employed (ROCE) | 9.93% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.68M |
| Profits Per Employee | 315,715 |
| Employee Count | 372 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OSL:GENO has paid 27.16 million in taxes.
| Income Tax | 27.16M |
| Effective Tax Rate | 18.78% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 19.49 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 32.60 |
| Average Volume (20 Days) | 248,563 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSL:GENO had revenue of NOK 1.37 billion and earned 117.45 million in profits. Earnings per share was 0.65.
| Revenue | 1.37B |
| Gross Profit | 887.04M |
| Operating Income | 138.56M |
| Pretax Income | 144.61M |
| Net Income | 117.45M |
| EBITDA | 203.54M |
| EBIT | 138.56M |
| Earnings Per Share (EPS) | 0.65 |
Balance Sheet
The company has 504.42 million in cash and 112.36 million in debt, with a net cash position of 392.06 million or 2.06 per share.
| Cash & Cash Equivalents | 504.42M |
| Total Debt | 112.36M |
| Net Cash | 392.06M |
| Net Cash Per Share | 2.06 |
| Equity (Book Value) | 1.27B |
| Book Value Per Share | 6.62 |
| Working Capital | 687.80M |
Cash Flow
In the last 12 months, operating cash flow was 113.64 million and capital expenditures -34.01 million, giving a free cash flow of 79.63 million.
| Operating Cash Flow | 113.64M |
| Capital Expenditures | -34.01M |
| Depreciation & Amortization | 64.99M |
| Net Borrowing | -112.53M |
| Free Cash Flow | 79.63M |
| FCF Per Share | 0.42 |
Margins
Gross margin is 64.77%, with operating and profit margins of 10.12% and 8.58%.
| Gross Margin | 64.77% |
| Operating Margin | 10.12% |
| Pretax Margin | 10.56% |
| Profit Margin | 8.58% |
| EBITDA Margin | 14.86% |
| EBIT Margin | 10.12% |
| FCF Margin | 5.81% |
Dividends & Yields
OSL:GENO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 16.74% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.78% |
| Shareholder Yield | -6.78% |
| Earnings Yield | 4.11% |
| FCF Yield | 2.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for OSL:GENO is 28.50, which is 79.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 28.50 |
| Price Target Difference | 79.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.45% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |